1ADNB

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Adalta Limited

🇦🇺 ASX

👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

1
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-08-22. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies.

📈 Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in 1ADNB

0

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in 1ADNB

N/A
1ADNB investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in 1ADNB also invest in...

BetaShares Global Cybersecurity ETF

HACK

HACK.AX was created on 2016-08-30 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The fund aims to track the performance of an index (before fees and expenses) that provides exposure to the leading companies in the global cybersecurity sector.

🙌 Performance (5Yr p.a)

16.41%

📊 Share price

$14.40 AUD

🇦🇺 EX AUSTRALIA

📈 HIGH PRICE GROWTH

🤖 TECHNOLOGY

Find Out More

AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The firm uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The firm's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. The company is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. The company co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.

🙌 Performance (5Yr p.a)

-16.15%

📊 Share price

$0.01 AUD

🧬 BIOTECHNOLOGY

Galan Lithium Ltd. engages in mineral exploration, acquisition, and evaluation. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-06-08. The firm is focused on its lithium brine projects located in the Hombre Muerto Basin in Argentina. The company holds two lithium brine projects across approximately 36,000 hectares on the Hombre Muerto salar. The firm's Hombre Muerto West (HMW) Project comprises exploration permits covering approximately 11,600 hectares. The HMW Project is located in the geological province of Puna, 90 kilometers (km) north of the town of Antofagasta de la Sierra, and to the west and south of the Salar del Hombre Muerto in Argentina. Its Candelas Project comprises over 14 exploration permits covering over 24,000 hectares hosted within an approximately 15km by 3-4 km wide structurally controlled basin. The company owns 100% of the tenement package that makes up the Greenbushes South Project which covers a total area of approximately 315 km2. The project is located over 250 km south of Perth in Western Australia.

🙌 Performance (5Yr p.a)

-11.32%

📊 Share price

$0.12 AUD

⛏️ MINING

Grange Resources Ltd. engages in the mining, processing, exploration, evaluation, and development of mineral resources and iron ore. The company is headquartered in Burnie, Tasmania. The Company’s principal activities consist of the mining, processing and sale of iron ore, and the ongoing exploration, evaluation and development of mineral resources. Its projects include Savage River, Port Latta and Southdown. The Savage River magnetite iron ore mine, approximately 100 kilometers (km) southwest of the city of Burnie. The Port Latta project is located approximately 70 km northwest of Burnie, and its 100%-owned pellet plant and port facility at Port Latta produces over 2.5 million tons of iron ore products annually. The Southdown Magnetite Project is located over 90 km east-northeast of Albany, and 10 km south-west of Wellstead in the Great Southern region of Western Australia. The company contains over 1.2 billion tons of mineral resources, including 388 million tons (Mt) of ore reserves.

🙌 Performance (5Yr p.a)

3.59%

📊 Share price

$0.23 AUD

⛏️ MINING

Hazer Group Ltd. engages in the research and development of novel graphite, and hydrogen production technology. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-12-02. The principal activity of the Company is the research and development of hydrogen and graphitic carbon production technology. The Company’s advanced technology enables the production of clean and economically competitive hydrogen and graphite, using a natural gas (or biogas) feedstock and iron-ore as the process catalyst. The firm has intellectual property rights to a technology (the Hazer Process), which enables the production of hydrogen gas from the thermo-catalytic decomposition of methane (natural gas) with low carbon dioxide emissions and the co-production of a high-purity graphite product. The firm's markets include industrial hydrogen, hydrogen mobility and synthetic graphite. The company has facilities, including a research and development lab and a fluid bed reactor pilot plant.

🙌 Performance (5Yr p.a)

-5.60%

📊 Share price

$0.36 AUD

🧪 CHEMICALS

Want more shares? Try these...

📊 Share price

$0.04 AUD